Investors dont't seem to like Osphena: Osphena (Ospemifene) is a selective estrogen receptor modulator (SERM) drug developed by Japanese pharmaceutical company Shionogi & Co (GM:SGIOF) that was approved earlier this year, although it is specifically used for women who experience pain during sex (dyspareunia). This is an effect of vaginal dryness, which is frequent in menopausal women who have lower estrogen levels. Osphena helps to rebuild the actual thickness of the vaginal wall without direct use of estrogen, which is novel. Although it is efficacious, Osphena has some major drawbacks with regards to its safety and use. Uncommon and possible side effects of the drug include stroke, blood clots, and endometrial cancer (cancer of the uterus). Common side effects include hot flashes, discharge, muscle spams, and increased sweating. While this therapy may replace standard estrogen therapy, it is dangerous. In addition, it is far from an equivalent to "female Viagra".
No bone, breast, or endometrial data but Dr. we have fancy commercials coming out soon....that's the dumbest shite I've heard.
Have you SEEN the prescriptions trickling in in the single digits in most territories each week? Seems like the docs don't give a shit about painful sex. Educate yourself by looking at the weekly data. You are being paid more than you are bringing in.
That post says it all. It says you have absolutely no idea what you're talking about; that you have no idea how capitalism works; that you think a product can survive if the media turns against it; that you think docs will use a systemic product that doesn't have safety data; and that you're obviously getting paid more than you're worth!
It was nice of corporate to give us those bonuses but they did that to not lose any reps and keep us motivated. However, it won't last long if Osphena doesn't start selling quick. Sales numbers vs what was expected is way off and everyone knows that. Why? Who knows. Super high expectations. Enjoy the way things are now bc next year we are going to go on goals...maybe lay offs soon
Dyspareunia is a relatively small volume market at this time. It is possible that it is under diagnosed and under treated. The reason that Osphena hasn't taken off like a rocket is that it is being marketed to a conservative specialty. A specialty group that is also being told by other sales people that the optimal therapy is a low dose local treatment. How can we change this? Ummm.... acting like sales people. You whiners complain about how this isn't a sales job but you don't seem to understand what it takes to be a sales person. Showing up to work occasionally, talking mainly about your kids, gossip, vacations, sports, entertainment news, or love life in the office; complaining about how life is so hard, and wondering why you aren't being given a bonus when neither you nor the company is meeting sales goals, is not what it takes to be a sales person.
Like you said "it's a small market for dysperunia" so the companys expectations vs reality are way off. The market research performed prior to the launch was poor and not accurate at all or we wouldn't be here. Why didn't they let us keep selling kapvay which was doing great? Who knows
They are not conservative. They are weary and wary. They were beaten up and sued over WHI for years. Why did we launch this very expensive product with minimal data against a product with 70 years of data and experience. The FDA states in the same black box warning that we have: any estrogen therapy should be at the lowest dose for the shortest period of time. How have the results so far surprised anyone. Management miscalculated and now they are blaming the sales team.
Shionogi just had FEDERAL WHISTLEBLOWER RETALIATION complaint filed on them. An employee manager reported a stroke that occurred in a patient that was on Osphena. They were terminated days later. Make sure you share this with your physicians. This is the last thing Shionogi wanted to happen.
